BNET Industries

SCOLR Pharma Inc.

(DDD) is in the Pharma Industry

Market Cap:$18.9M
Last Fiscal Year Sales:$958.3K
  • Public
  • US
Dow Jones Description

SCOLR uses its proprietary CDT platform to develop extended release solid oral pharmaceutical medications and nutritional supplements. The Company markets its dietary supplement products through private label retailers in the U.S. and partners with industry leaders for the marketing and business development of its pharmaceutical and OTC products and services internationally. The Company's technology platform is based on a portfolio of drug delivery patents. Its platform offers lower cost, ease of formulation and scale up advantages over competing technologies. SCOLR's first technology was licensed from Temple University in 1998 and since then has expanded to include three patented drug delivery technologies applicable to a wide variety of common and challenging classes of drugs and nutritional ingredients (U.S. patent Nos. 6,090,411; 6,337,091; 6,517,868; 6,936,275; 7,229,642; and Patents pending). Founded in 1983 as BioTechniques Laboratories, the Company's original mission was to research and manufacture probiotic strains for human and animal use. SCOLR became a publicly traded corporation in 1995 and expanded into product formulation and drug delivery in 1998. On December 31, 2003, the Company has divested itself of its nutraceutical and probiotic businesses to become a fully-focused specialty pharma company commercializing its broadly applicable CDT platform of drug delivery technologies. ...

Number of Employees 19
Contact Information

19204 North Creek Parkway

Suite 100

Bothell, Washington 98011

scolr.com

4253681050

NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413

Recent Events

  • SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results

    11/07/09 - Financial Announcement - View Story

  • NYSE questions Scolr Pharma's future

    9/18/09 - Financial Announcement - View Story

  • Metabasis CEO jumps to Merck

    9/02/09 - Mgmt. Change Entering - CEO - View Story

  • SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results

    8/07/09 - Financial Announcement - View Story

  • Company and People Notes: Synta and GSK End Agreement; WuXi Appoints US VP; More...

    6/25/09 - Mgmt. Change Leaving - CEO - View Story

News & Analysis

scolr pharma inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Bruce Morra CEO
Daniel O. Wilds Chief Executive Officer
Alan M. Mitchel Senior Vice President, Chief Legal Officer
Richard M Levy Chief Financial Officer, V.P. Finance
Stephen J. Turner Vice President, Chief Technical Officer
Jeffrey B. Reich Vice President of Cramer, Rosenthal & Mcglynn
Tanya Raco Associate V.P. of Quality and Regulatory Affairs
Reza Fassihi Professor of Biopharmaceutics and Industrial Pharmacy

Board of Directors

Name (plus bio) Position
Herbert L. Lucas Chairman
Michael N Taglich Chairman of Scolr Pharma's Board of Directors
Gregory Weaver Board of Directors
Hans Mueller Board of Directors
Michael Sorell Board of Directors
Randall L.W. Caudill Member of the Board
Reich Jeffrey Board of Directors
Wayne L. Pines Board of Directors

Dr. Bruce S. Morra has been the President and CEO of SCOLR Pharma, Inc. since January 2009. He has been an independent consultant since February 2000. He was the President of West Drug Delivery Systems, a division of West Pharmaceutical Services, Inc., from April 2003 through December 2004. He served as the President, COO, CFO and board member of Biopore Corporation and Polygenetics, Inc., two related companies developing technology for drug delivery and medical devices for biomedical and industrial applications from 1998 through 2002, then served as Executive Vice President, Chief Business Officer and board member from 2002 to 2004. From 1993 through 2000, he served as President and COO of Flamel Technologies, Inc., a company developing, manufacturing and licensing drug and agrochemical delivery technologies and products. Dr. Morra previously served as director of Unigene from 2001 to 2003. He currently serves as a director for SCOLR Pharma, Inc. and InforMedix Holdings, Inc. Dr. Morra holds a Ph.D. in polymer science and engineering and an M.B.A. from the University of Massachusetts, Amherst and a B.S.E. in chemical engineering from Princeton University.

Organization Position Status
Scolr Pharma, Inc. CEO Current
Scolr Pharma, Inc. Consultant Former
Informedix, Inc. Director, Nominee Current
Unigene Laboratories, Inc. Board of Directors Current
Scolr Pharma, Inc. Board of Directors Current
Informedix, Inc. Board of Directors Current
Informedix Holdings, Inc. Director Current
Biopharm Solutions, Inc Director Current
Flamel Technologies Incorporated President Former
Polygenetics Inc President Former
West Pharmaceutical Services, Inc. President Former
Flamel Technologies Incorporated Coo Former
Polygenetics Inc Coo Former
Progenitor Cell Therapy, LLC Chief Business Officer Former
Flamel Technologies Incorporated Founder Former
Polygenetics Inc Board Member Former
Princeton University Ph.D. In Polymer Science Former
Princeton University B.S.E. Former

Daniel O. Wilds , is our president and chief executive officer. From 1998 to July 2003, Mr. Wilds served as chairman, president and chief executive officer of Northwest Biotherapeutics, Inc., a biotechnology company focused on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. From 1997 to 1998, Mr. Wilds served as president and chief executive officer of Shiloov Biotechnologies (USA), Inc. From 1992 to 1996, Mr. Wilds served as president and chief executive officer of Adeza Biomedical Corporation, prior to which he served as president and chief executive officer of Medisense, Inc. and president of Baxter's Chemotherapy Service. Mr. Wilds has also served as president and chief operating officer of Travenol-Genentech, Inc., a joint venture between Baxter International and Genentech, Inc., and has held other domestic and international senior management positions in the biomedical and biopharmaceutical fields. Mr. Wilds currently serves on the board of directors of Helix BioMedix, Inc. Mr. Wilds holds a B.A. from California State University, Los Angeles and an M.B.A. from Northwestern University.

Organization Position Status
Scolr Pharma, Inc. Chief Executive Officer Current
Scolr Pharma, Inc. President Current
Helix Biomedix, Inc. Board of Directors Current
Scolr Pharma, Inc. Board of Directors Current
Adeza Biomedical Corporation CEO Former
Northwest Biotherapeutics, Inc. CEO Former
Northwest Biotherapeutics, Inc. President Former
Adeza Biomedical Corporation President Former
Northwest Biotherapeutics, Inc. Chairman Former
Northwestern University MBA Former
California State University BA Former
University of Oxford Degree Former
Helix Biomedix, Inc. Member Former

Organization Position Status
Scolr Pharma, Inc. Senior Vice President, Chief Legal Officer Current
Garvey Schubert Barer Counsel Former
Duke Law School Llb Former

Organization Position Status
Scolr Pharma, Inc. Chief Financial Officer, V.P. Finance Current
Ernst & Whinney Former
University of California, Santa Barbara BA In Business Economics Former
University of California, Santa Barbara Degree In Business Economics and Accounting Former

Organization Position Status
Scolr Pharma, Inc. Vice President, Chief Technical Officer Current
Scolr Pharma, Inc. Board of Directors Current
American Association of Pharmaceutical Scientists Former
Western Washington University BS In Biology Former

Organization Position Status
Cramer Rosenthal McGlynn LLC Vice President Current
Scolr Pharma, Inc. Vice President of Cramer, Rosenthal & Mcglynn Current
CRM Funds Vice President Current
Cramer Rosenthal McGlynn LLC Analyst Current
Scolr Pharma, Inc. Board of Directors Current
Neurologix, Inc. Board of Directors Current
Merlin Biomed Group Portfolio Manager Former
Merlin Biomed Group Senior Analyst Former
Weill Medical College of Cornell University Md Former
State University of New York at Binghamton BA Former
Weill Medical College of Cornell University Medical Degree Former

Organization Position Status
Scolr Pharma, Inc. Associate V.P. of Quality and Regulatory Affairs Current

Organization Position Status
Scolr Pharma, Inc. Professor of Biopharmaceutics and Industrial Pharmacy Current
Scolr Pharma, Inc. Board of Directors Current
Rhodes University Senior Lecturer Former
Temple University Director Former

Organization Position Status
Scolr Pharma, Inc. Chairman Current
Scolr Pharma, Inc. Board of Directors Current
Princeton University member Former
J. Paul Getty Trust Board of Directors Former
Electronic Clearing House, Inc. Board of Directors Former
Car Nation Director Former
Los Angeles County Museum of Art Board of Directors Former
Harvard University MBA Former
Princeton University B.A. Degree In History Former
J. Paul Getty Trust Trustee Former
Los Angeles County Museum of Art Trustee Former

Michael N. Taglich is a co-founder and has been President of Taglich Brothers, Inc. since its founding in 1992. Taglich Brothers was ranked #1 in investment performance by Investars.com for performance for the four years ended 12/31/05. Mr. Taglich served as director or chairman of a number of public and private companies. Along with his wife, Mr. Taglich was benefactor of the year of the Tommorow's Hope Foundation, which benefits Catholic schools in the Diocese of Rockville. Mr. Taglich earned a Bachelors degree in Business from New York University.

Organization Position Status
Taglich Brothers, Inc. Co-Founder, President & Chairman Current
Informed Investors, Inc. Co-Founder Current
Taglich Brothers, Inc. Owner Former
WSI Industries, Inc. Chairman of the Board Former
Dilon Technologies, LLC Director Current
Premier Funding, Inc. Director Current
Scolr Pharma, Inc. Board of Directors Current
WSI Industries, Inc. agent Former
New York University BS Former

Organization Position Status
Talyst Chief Financial Officer Former
Celsion Corporation Board of Directors Current
Prism Technologies, Inc. Chief Financial Officer Former
ILEX Oncology, Inc. Chief Financial Officer Former
MDRNA, Inc. Chief Financial Officer Former
Andersen Corporation Former
MDRNA, Inc. Secretary Former
Boston College MBA Former
Trinity University B.S. In Accounting Former

Organization Position Status
Hypnion, Inc. Current
Idera Pharmaceuticals, Inc. Director Current
Transmolecular, Inc. Board of Directors Current
Scolr Pharma, Inc. Board of Directors Current
Sandoz Former
University Corp. Ph.D. In Actuarial Sciences and Math Former

Organization Position Status
Scolr Pharma, Inc. Board of Directors Current
Morgan Stanley Principal Former

Organization Position Status
VaxGen, Inc. Board of Directors Current
Northwest Biotherapeutics, Inc. Board of Directors Current
Scolr Pharma, Inc. Member of the Board Current
Helix Biomedix, Inc. Board of Directors Current
The First Boston Corporation vice president Former
Morgan Grenfell Executive Director Former
Pru-One Inc. co-head Former
Morgan Grenfell Co-Head of Mergers and Acquisitions Former
University of Oxford doctorate of philosophy while a Rhodes Scholar Former
Yale University Master's Degree In Public and Private Management Former

Organization Position Status
Scolr Pharma, Inc. Board of Directors Current

Organization Position Status
The Patient Channel President, Regulatory Services and Health Care, Employer: Apco Worldwide Current
APCO Worldwide President Current
Exceltrials, Inc. Consultant Current
K Street Associates LLC Consultant Current
Scientific Advantage, LLC Senior Regulatory Counselor Current
Medstar Research Institute Chairman of the Board Current
The Patient Channel Board of Directors Current
Scolr Pharma, Inc. Board of Directors Current
Exceltrials, Inc. Board of Directors Current
Clinlaw Board of Directors Current
Northwest Biotherapeutics, Inc. Director Current
Public Affairs LLC Chief of Press Relations Former
Fda.Com Chief of Press Relations Former
Burson-Marsteller Executive Vice President Former
Public Affairs LLC Associate Commissioner Former
Rutgers University Former

Executive News

  • Company and People Notes: Synta and GSK End Agreement; WuXi Appoints US VP; More...

    Pharmaceutical Technology - 6/25/09 - View Story

  • Calcionics Appoints Daniel O. Wilds Executive Chairman

    Pharma Live - 6/24/09 - View Story

advertisement
     DDD $0.46 0.00 (0.00% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 42,536
Shares Outstanding 41.10M
Market Cap 18.9M
Year High 1.1
Year Low 0.25
Earnings Per Share -0.14
P/E Ratio -3.29
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement
Click Here